ARTEMIDE-HCC01: Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Occurrence of AEs and SAEs will be graded according to the revised NCI CTCAE v5.0.

PFS according to RECIST 1.1

ORR according to RECIST 1.1

OS

PFS

ORR

DoR

Association of PD-L1 expression level with: • OS

Association of PD-L1 expression level with: • PFS per RECIST 1.1

Association of PD-L1 expression level with: • ORR per RECIST 1.1

Association of PD-L1 expression level with: •DoR per RECIST 1.1

Association of PD-L1 expression level with: OS

Association of PD-L1 expression level with: PFS per RECIST 1.1

Association of PD-L1 expression level with: ORR per RECIST 1.1

Association of PD-L1 expression level with: DoR per RECIST 1.1

Presence of ADAs for tremelimumab and rilvegostomig

OS is defined as the time from randomisation until the date of death due to any cause.